Quick Facts

• Chronic Sialorrhea: Assists in the management of long-lasting, excessive saliva production in adults and children aged 2 years and older.
• Upper Limb Spasticity: Supports the treatment of increased muscle stiffness in the arm in adults and some pediatric patients (2–17 years).
• Cervical Dystonia: May contribute to decreasing the severity of abnormal head position and associated neck pain in adults.
• Blepharospasm: Indicated for managing involuntary eyelid spasms in adult patients.
• Glabellar Lines: Provides temporary improvement in the appearance of certain moderate to severe frown lines between the eyebrows in adults.

---

Xeomeen is a prescription treatment that may be suitable for managing several conditions characterized by abnormal muscle activity or excessive glandular function. The therapeutic goal is to help reduce the activity in specific muscles or glands associated with these conditions.

In the setting of upper limb spasticity, Xeomeen may assist in the management of muscle stiffness and associated involuntary muscle contractions in the arms. For adults with cervical dystonia, it is used to help address the symptoms of abnormal head posture and the severity of neck pain.

Xeomeen is also indicated for the management of chronic sialorrhea, a condition involving excessive drooling, in both adults and pediatric patients aged 2 and above. Furthermore, it provides management support for blepharospasm, which involves involuntary spasms of the eyelids, as well as providing temporary improvement for the appearance of specific moderate to severe frown lines in adults. The range of approved indications is established through clinical assessment and regulatory review.

Official Population Eligibility for Xeomeen

The eligibility for Xeomeen (IncobotulinumtoxinA) is strictly defined by regulatory documents, specifying which populations are approved for use and which are explicitly excluded.

Contraindicated Populations (Must Not Use)	Eligibility-Based Restrictions
Known hypersensitivity to any botulinum toxin product or any component of the formulation.	Use in pregnancy is advised only if the potential benefit justifies the potential risk to the fetus.
Presence of infection or inflammation at the proposed injection site(s).	Lactation status is unknown; caution is recommended for nursing women.

Age and Condition-Specific Rules:

Xeomeen is generally approved for adults (18 years and older) across all labeled indications. For children, use is restricted by age and condition:

• Pediatric Patients (2–17 years): Approved for Chronic Sialorrhea and Upper Limb Spasticity.
• Pediatric Exclusion: Use for spasticity caused by cerebral palsy is explicitly excluded from the approved label for pediatric Upper Limb Spasticity.
• Not Established: Safety and effectiveness are not established for children under 2 years of age for any indication, or for patients under 18 years for Cervical Dystonia or Blepharospasm.

Patients with pre-existing neuromuscular disorders (e.g., Myasthenia Gravis, Lambert-Eaton Syndrome) may be at an officially documented increased risk of systemic effects and require specific caution.

The official regulatory profile for Xeomeen (IncobotulinumtoxinA) focuses primarily on pharmacodynamic interactions that may increase the effect of the neurotoxin, rather than metabolic or transporter-based interactions.

Documented Interaction Patterns

The following interaction statements are recorded in authoritative government regulatory documents (e.g., FDA and EMA labels):

Interacting Product Category	Interaction Statement (as per label)
Neuromuscular Blocking Agents	Co-administration with agents that interfere with neuromuscular transmission, such as aminoglycoside antibiotics and spectinomycin, may potentiate the effect of the toxin.
Muscle Relaxants	Requires close observation upon co-administration, as the effect of Xeomeen may be potentiated.
Anticholinergic Drugs	Co-administration may potentiate the systemic anticholinergic effects of the botulinum toxin product.
Other Botulinum Toxin Products	The use of different botulinum neurotoxin products at the same time or within several months is associated with a risk of excessive neuromuscular weakness.

Population-Specific Interaction Notes

The clinical effects of treatment are noted to be exacerbated in individuals with pre-existing peripheral motor neuropathic diseases or neuromuscular junctional disorders (e.g., Myasthenia Gravis), reflecting a heightened susceptibility to the potentiated effects.

No specific interactions are documented in the official labeling for Xeomeen regarding food, alcohol, herbal products, or supplements, nor are there listed interactions related to CYP enzymes or drug transporters.

Targeted Molecular Blockade of Nerve Signaling

Xeomeen (IncobotulinumtoxinA) exerts its effect through a highly precise, multi-stage mechanism confined to peripheral cholinergic nerve endings. The toxin's heavy chain first binds to receptors on the nerve surface, allowing the entire molecule to be internalized via endocytosis. Once inside the nerve terminal, the light chain functions as a zinc-dependent endopeptidase (an enzyme). This enzyme selectively cleaves the structural protein SNAP-25, an essential component of the SNARE complex . This proteolytic action effectively blocks the release of the neurotransmitter acetylcholine (ACh) from its synaptic vesicles.

Mechanism of Localized Physiological Consequence

The resulting blockade of ACh release directly silences efferent signaling at the neuromuscular junction. This physical inability to transmit a signal leads to a state of temporary, localized flaccid paralysis or localized muscle weakening, or a reduction in secretion from injected glandular tissue. Function is recovered spontaneously as the nerve terminal regenerates and synthesizes new SNAP-25 protein to rebuild the SNARE complex.

How to use Xeomeen: Official Administration Guidelines

Xeomeen (incobotulinumtoxinA) is administered exclusively by injection and must be prepared by a healthcare professional prior to use. It is supplied as a lyophilized powder and requires reconstitution with sterile, preservative-free 0.9% Sodium Chloride Injection, USP. The vial must be mixed gently by rotation, not shaking, to avoid denaturation of the product.

Administration and Dosing

The route of administration is either Intramuscular (for spasticity, cervical dystonia, and blepharospasm) or Intraglandular (for chronic sialorrhea). Treatment is highly individualized based on the specific condition, muscle size, and patient response. Dosing is measured in Units and must be precisely prepared according to approved indications.

The maximum cumulative dose for any indication in a single treatment session is strictly limited to 400 Units. Specific dosage examples include: 100 Units total for chronic sialorrhea (using ultrasound guidance for needle placement in the salivary glands) and 20 Units total for glabellar lines.

Frequency and Procedural Rules

Treatment frequency is constraint-based and is not a daily or weekly schedule. Retreatment for most conditions, such as upper limb spasticity and blepharospasm, should not occur sooner than every 12 weeks. For glabellar lines, the minimum interval is three months. For chronic sialorrhea, retreatment is permitted no sooner than every 16 weeks.

Once reconstituted, the solution must be used for only one injection session and for only one patient. The reconstituted product must be stored in a refrigerator (2°C to 8°C) and used within 24 hours of preparation.

Age-Specific Use: Pediatric dosing for upper limb spasticity is weight-based, not to exceed 16 Units/kg or 400 Units total.

Research evidence / Overview of Studies for Xeomeen

---

Evidence for Management of Abnormal Muscle Activity (Dystonia and Spasticity)

Clinical evaluation has relied on different types of studies, including randomized controlled trials (RCTs), where researchers explored whether symptoms change over time. These short-term studies were often followed by long-term open-label extension periods for continued observation. The research focuses on how symptoms are measured in conditions characterized by fluctuating or episodic muscle contractions.

Research on Cervical Dystonia

Studies were conducted to examine whether a single administration was associated with changes in symptom intensity or variability in adults diagnosed with cervical dystonia, a condition involving abnormal head position and associated neck pain. The research explored the use of specific assessment scales, such as the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). The short-term research exploring symptom changes is better characterized than the long-term patterns, which are largely based on open-label studies without a control group. The initial studies used fixed-dose regimens, limiting insight into individualized dosing.

Research on Upper Limb Spasticity

Research examined Xeomeen in studies exploring conditions marked by functional limitations and muscle stiffness in the arms, including adults and pediatric patients aged 2 to 17 years. Researchers studied changes in muscle tone using objective scales like the modified Ashworth Scale (MAS). Studies typically followed patients for about 12 weeks. Data exploring causes of spasticity other than post-stroke etiology remains less extensive in adult cohorts.

---

Evidence for Management of Excessive Glandular Function and Involuntary Spasms

Research on Chronic Sialorrhea (Excessive Drooling)

Xeomeen was evaluated in short-term randomized, double-blind, placebo-controlled trials for chronic sialorrhea. Research examined objective measures of salivary production (uSFR) and patient-reported outcomes (DSFS) in adults and children aged 2 years and older. Certainty remains low regarding the full range of long-term outcomes, as the regulatory measurement period was relatively short.

Research on Blepharospasm (Eyelid Spasms)

Studies explored Xeomeen in research examining blepharospasm in adults. These trials examined outcomes related to the severity and frequency of the spasms, often measured using the Jankovic Rating Scale (JRS). One research limitation is the relatively short follow-up duration of the initial placebo-controlled studies.

---

What is Still Uncertain About the Research Evidence

The available evidence base presents limitations, including that comparative evidence is lacking for many long-term outcomes against other treatments. Follow-up durations were limited in the placebo-controlled phases, and reliance on subjective assessments in some studies is a recognized limitation that contributes to uncertainty.

Key Studies & References

1. Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States (NCT01287247)

Common questions about Xeomeen (FAQ)

Q: What is Xeomeen used for?

A: Xeomeen (incobotulinumtoxinA) is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines) associated with corrugator and/or procerus muscle activity in adults. It may also be used in certain other therapeutic applications as determined by a healthcare provider, such as for cervical dystonia or blepharospasm.

Q: How long does the effect of Xeomeen last?

A: The duration of effect for Xeomeen may vary among individuals. Clinical trials indicate that, for aesthetic use, the effect generally lasts up to three months. A healthcare provider can offer personalized expectations based on the specific treatment area and individual response.

Q: Is Xeomeen the same as Botox or Dysport?

A: Xeomeen contains the same active ingredient, botulinum toxin type A, as Botox and Dysport. However, Xeomeen is purified and contains no complexing proteins, which is a structural difference from some other available botulinum toxin products. All are prescription medications, and a healthcare provider determines the most appropriate product for a patient's needs.

Q: Are there important safety warnings I should know about?

A: Like all botulinum toxin products, there is a risk of distant spread of the toxin effects from the injection site. This can cause symptoms such as swallowing difficulties (dysphagia), breathing problems, and muscle weakness, which can occur hours to weeks after injection. It is important to seek immediate medical attention if you experience these symptoms. Your prescribing information contains a boxed warning about this potential risk.

Official Storage and Disposal Guidelines

Xeomeen is a single-use biological product whose stability and handling requirements are precisely defined by regulatory documents to ensure product integrity.

Storage State	Temperature and Time Constraint
Unreconstituted Powder	Does not require refrigeration; store at controlled room temperature (up to 25 C). Protect from light.
Reconstituted Solution	Must be stored in a refrigerator (2 C to 8 C).

Stability and Handling: The solution must be administered within 24 hours after reconstitution with preservative-free 0.9% sodium chloride. The product should be mixed gently by swirling, not shaking, and must be discarded if the resulting solution is cloudy or contains particulate matter. The vial is intended for only one injection session and one patient.

Disposal: Due to the nature of the active ingredient, any unused product, expired vials, or waste materials must be disposed of as medical waste in accordance with local, regulated pharmaceutical disposal requirements. Keep the medicine out of the sight and reach of children.